Análisis de la acción Nyxoah SA (NYXH)

Análisis de IA of Nyxoah SA (NYXH)

Mantener

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.

Métricas de valoración

El PER previsto actual de Nyxoah SA (NYXH) es 0.00, frente a su media de 5 años de -4.19.

PER previsto

Sobrevalorado

Media 5A P/E

-4.19

P/E actual

0.00

Sobrevalorada

-0.85

Infravalorada

-7.52

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-3.12

EV/EBITDA actual

-0.42

Sobrevalorada

-0.25

Infravalorada

-5.99

Precio/ventas previsto

Valor razonable

Media 5A P/S

23.23

P/S actual

1.26

Sobrevalorada

45.85

Infravalorada

0.61

Escenarios de precio de Alphio AI para NYXH

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%NYXH

$9.24

Precio del escenario

B

Base

Base · 50%NYXH

$7.86

Precio del escenario

B

Bajista

Bajista · 25%NYXH

$7.48

Precio del escenario

Ballenas con NYXH en cartera

P

Pentwater Capital Management LP

+ Con en carteraNYXH

-3.88%

Rentabilidad a 3 meses

Preguntas frecuentes sobre NYXH, respondidas por Alphio AI

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin. It operates in the Healthcare sector.

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.